RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 Rapid Sustained HCV Viral Load Reductions Achieved with ACH-3102 Plus SOF
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 48
SP 9
OP 10
DO 10.1177/155989771448003
UL http://mdc.sagepub.com/content/14/48/9.abstract
AB ACH-3102 is a second-generation hepatitis C virus (HCV) nonstructural 5A (NS5A) protein inhibitor with potent activity against HCV genotype (GT)-1 through GT-6. An ongoing phase 2 open-label study evaluated the safety and efficacy of 8 and 6 weeks of ACH-3102 plus sofosbuvir therapy in treatment-naïve patients with chronic HCV GT-1 infection, as discussed in this article.